Bionano Genomics (NASDAQ:BNGO) Posts Earnings Results, Beats Estimates By $0.12 EPS

Posted by Francis Steltz on May 13th, 2026

Bionano Genomics (NASDAQ:BNGO – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.12, FiscalAI reports. The firm had revenue of $6.69 million for the quarter, compared to analyst estimates of $6.57 million. Bionano Genomics had a negative net margin of 92.59% and a negative return on equity of 56.22%.

Bionano Genomics Trading Down 0.4%

Shares of BNGO stock traded down $0.01 on Wednesday, hitting $1.26. 312,942 shares of the company’s stock traded hands, compared to its average volume of 284,490. The stock has a market capitalization of $13.92 million, a price-to-earnings ratio of -0.26 and a beta of 1.62. Bionano Genomics has a one year low of $1.06 and a one year high of $5.50. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.74 and a current ratio of 1.98. The company’s fifty day simple moving average is $1.19 and its 200 day simple moving average is $1.40.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. HC Wainwright decreased their price target on shares of Bionano Genomics from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Weiss Ratings raised shares of Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.00.

Check Out Our Latest Report on BNGO

Institutional Investors Weigh In On Bionano Genomics

A number of large investors have recently added to or reduced their stakes in BNGO. Jane Street Group LLC bought a new stake in Bionano Genomics in the 4th quarter worth $34,000. Renaissance Technologies LLC bought a new stake in Bionano Genomics in the 4th quarter worth $57,000. Carret Asset Management LLC grew its holdings in Bionano Genomics by 76.4% in the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock worth $67,000 after acquiring an additional 19,100 shares during the last quarter. Geode Capital Management LLC grew its holdings in Bionano Genomics by 148.8% in the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock worth $102,000 after acquiring an additional 39,928 shares during the last quarter. Finally, DRW Securities LLC bought a new stake in Bionano Genomics in the 4th quarter worth $258,000. Institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

(Get Free Report)

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.